KEFLEX

Compare KEFLEX  to:
Compare
Compare

Generic Name for KEFLEX

Cephalexin 250mg, 333mg, 500mg, 750mg; caps.

Legal Classification:

Rx

Pharmacological Class for KEFLEX

Cephalosporin.

Manufacturer of KEFLEX

MiddleBrook Pharmaceuticals

Indications for KEFLEX

Susceptible infections including otitis media, skin and skin structure, bone, respiratory or genitourinary tract.

Adult dose for KEFLEX

1–4g/day in divided doses. Usual dose: 250mg every 6 hours. Strep pharyngitis, skin and skin structure, and uncomplicated cystitis (>15 years of age): 500mg every 12 hours. Treat cystitis for 7–14 days. Max 4g/day.

Children's dosing for KEFLEX

25–50mg/kg per day in divided doses; max 100mg/kg per day. Otitis media: 75–100mg/kg per day in 4 divided doses. Strep pharyngitis (>1 year of age) or skin and skin structure: may give in 2 divided doses every 12 hours.

Warnings/Precautions for KEFLEX

Penicillin or other allergy. Severe renal dysfunction. GI disease (esp. colitis). Discontinue if colitis occurs and treat. Pregnancy (Cat.B). Nursing mothers.

Interactions for KEFLEX

Potentiates metformin (monitor and adjust metformin dose). Potentiated by probenecid. May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln.

Adverse Reactions for KEFLEX

Diarrhea, other GI disturbances, dizziness, fatigue, headache, hypersensitivity reactions, itch; rare: blood dyscrasias, elevated liver enzymes.

How is KEFLEX supplied?

Caps 250mg, 500mg—20, 100
333mg—(available soon)
750mg—50

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions